Eisai and Biogen have submitted an application to the FDA for a new Alzheimer’s treatment, LEQEMBI. The new subcutaneous autoinjector offers a once-weekly starting dose option for patients with early AD, potentially reducing healthcare resources and providing more flexibility in treatment. If approved, this new dosing regimen could expand treatment options for patients and caregivers, with the ability to choose between IV and SC delivery methods. LEQEMBI is currently approved in 48 countries and under review in 10 more, with Eisai leading global development efforts.

Read more at Nasdaq: Eisai Begins Rolling SBLA Submission For LEQEMBI IQLIK Subcutaneous Autoinjector